Measurement of serum pancreatic secretory trypsin inhibitor (PSTI) for the evaluation as a marker for pancreatic diseases

Conference · Wed May 01 00:00:00 EDT 1985 · J. Nucl. Med.; (United States)

OSTI ID:7031339

Sasaki, Y; Tsujino, D; Noguchi, M; Someya, K

Clinical usefulness of measuring PSTI in sera was studied using a new RIA kit produced by Shionogi Pharmaceutical Co. The assessment of the kit performance was satisfactory with good precision (1.6-6.9% in C.V.), reproducibility (5.0-6.0%), sensitivity (>2.Ong/ml), recovery test (98-109%, m101) and linear dilution test results. Serum PSTI levels in 71 normal controls were 12.0 + 5.0 ng/ml(m+S.D.) with higher values in subjects over 60 y.o. (14.2 +- 4.2 in 60-69 y.o. and 18.9 +- 6.5 over 70 y.o.). Serum PSTI levels were measured in 183 patients with various benign diseases (BD) and 251 cancer patients (CA). Among BD relatively high positive (>30ng/ml) ratios were observed in acute pancreatitis(40%, N=15), chronic pancreatitis(23.1%,13), pneumonia(23.5%,23) in contrast to low levels in acute hepatitis (6.7%,15), chronic hepatitis (8.0%, 25), liver cirrhosis (10.3%,29) and others (11.1%,25) including 2 chronic renal failure (220 and 465 ng/ml). In a patient with acute pancreatitis followed from the onset of the attack PSTI levels revealed 2 peaks on the 1st and 4th day. Serum PSTI correlated with clinical courses better than serum amylase which declined faster than PSTI. Among CA relatively high positive ratios were seen in CA of pancreas(46.7%,30), biliary tract (52.6%,19) and primary hepatoma (58.8%,34) in contrast to low levels in CA of esophagus (18.2%,11), stomach (16.7%, 78), colon (21.6%, 37), lung (8.0%, 25) and breast (0%.17). Measurement of PSTI should provide a clinical indicator for pancreatic diseases complementing existing markers such as amylase, lipase, elastase 1 and trypsin.

• Research Organization: Toho Univ. and St. Marianna Univ., Tokyo
• OSTI ID: 7031339
• Report Number(s): CONF-850611-; TRN: 87-010729
• Journal Information: J. Nucl. Med.; (United States), Vol. 26:5; Conference: 32. annual meeting of the Society of Nuclear Medicine, Houston, TX, USA, 2 Jun 1985
• Country of Publication: United States
• Language: English

Related Subjects

62 RADIOLOGY AND NUCLEAR MEDICINE
DIGESTIVE SYSTEM DISEASES
BIOLOGICAL MARKERS
PANCREAS
ENDOCRINE DISEASES
NEOPLASMS
PEPTIDE HORMONES
BLOOD CHEMISTRY
RADIOIMMUNOASSAY
BILIARY TRACT
LARGE INTESTINE
LIVER
LUNGS
MAMMARY GLANDS
PATIENTS
TRYPSIN
BODY
DIGESTIVE SYSTEM
DISEASES
ENDOCRINE GLANDS
ENZYMES
GASTROINTESTINAL TRACT
GLANDS
HORMONES
HYDROLASES
IMMUNOASSAY
IMMUNOLOGY
INTESTINES
ISOTOPE APPLICATIONS
ORGANS
PEPTIDE HYDROLASES
RADIOASSAY
RADIOIMMUNOLOGY
RESPIRATORY SYSTEM
SERINE PROTEINASES
TRACER TECHNIQUES
550601* - Medicine- Unsealed Radionuclides in Diagnostics